Celgene Corp. will pay $35 million upfront under a collaboration announced Oct. 3 with VentiRx Pharmaceuticals Inc. to develop a novel, Toll-like receptor 8 (TLR8) agonist, VTX-2337, in cancer indications. The two companies will advance the compound in a pair of Phase II trials in ovarian and head-and-neck cancer over the next few years under an exclusive, worldwide partnership that also gives Celgene the option to purchase VentiRx.
In-licensed from Array BioPharma Inc. in 2007, ‘2337 is an immunotherapy that directly activates human myeloid dendritic cells, monocytes...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?